International Journal of Clinical Research

Objective To explore the clinical efficacy of human immunoglobulin combined with erythromycin in the treatment of neonatal severe infectious pneumonia and its effect on inflammatory markers. Methods 60 cases of neonatal severe infectious pneumonia in our hospital from March 2022 to March 2023 were selected and divided into two groups according to random sampling method. The control group (30 cases) was treated with erythromycin, and the treatment group (30 cases) was treated with human immunoglobulin on the basis of the control group. The levels of inflammatory markers (IL-6 PCT、WBC、CRP), The clinical efficacy of the two groups after treatment and the adverse reactions of newborns in the two groups during treatment were compared. Results the inflammatory markers in the two groups were significantly reduced after treatment, and the levels of IL-6, PCT, WBC, CRP in the treatment group were lower than those in the control group, and the clinical efficiency of the treatment group was higher than that of the control group (P < 0.05); There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P > 0.05). Conclusion the combined application of human immunoglobulin and erythromycin in the treatment of neonatal severe infectious pneumonia can significantly improve the therapeutic effect, reduce the inflammatory level of children, and ensure the safety of medication.

Newborn; Severe; Infectious pneumonia; Human immunoglobulin; Erythromycin